New Antibody-Drug conjugate KIVU-107 enters first human trials for Hard-to-Treat cancers

NCT ID NCT07229313

Recruiting now Disease control Sponsor: Kivu Bioscience Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KIVU-107 (an antibody-drug conjugate targeting PTK7)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early (Phase 1) and small trial (76 people), so safety and effectiveness are not yet known. The drug may cause side effects or not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCE SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cervical cancer colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm esophageal squamous cell carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma malignant pancreatic neoplasm Neoplasm Metastasis non-small cell lung carcinoma ovarian cancer pancreatic neoplasm sarcoma small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCE SOLID TUMORS BREAST CANCER CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER ESOPHAGEAL SQUAMOUS CELL CANCER GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA NON-SMALL CELL LUNG CANCER OVARIAN CANCER (OVCA) PANCREATIC CANCER SARCOMA SMALL CELL LUNG CANCER

Contacts and locations

Locations

Kivu Trial Site
RECRUITING

Santa Monica, California, 90403, United States
Kivu Trial Site
RECRUITING

Camperdown, New South Wales, 2050, Australia
Kivu Trial Site
RECRUITING

Sydney, New South Wales, Australia
Kivu Trial Site
RECRUITING

Brisbane, Queensland, Australia
Kivu Trial Site
RECRUITING

Adelaide, South Australia, Australia
Kivu Trial Site
RECRUITING

Geelong, Victoria, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.